
https://www.science.org/content/blog-post/plenty-tar-go-around
# Plenty of Tar to Go Around (January 2006)

## 1. SUMMARY

The article examines the fallout from the South Korean stem cell scandal involving researcher Hwang Woo-suk, whose papers on human embryonic stem cells were revealed to be fabricated and subsequently retracted from the journal *Science*. The author discusses criticism from Dr. Benjamin Lewin, founder of the journal *Cell*, who publicly stated that *Science* and *Nature* "don't have the reputation for rigorous review" and should have caught the duplicate photos in Hwang's paper. The author notes the irony that *Cell Press* (which publishes *Immunity*) also published compromised work, highlighting that research misconduct occurs across all top-tier journals and suggesting that focusing blame solely on *Science* is hypocritical.

## 2. HISTORY

The Hwang Woo-suk stem cell scandal of 2005-2006 revealed that his team's breakthrough claims—including creating the first cloned human embryonic stem cells—were fraudulent. Following the initial revelations in late 2005, both of Hwang's landmark *Science* papers were retracted in January 2006.

In the years following this scandal, the scientific publication landscape saw significant changes. While no major reforms fundamentally altered journal hierarchies (*Science*, *Nature*, and *Cell* remain top-tier venues), the incident contributed to several trends: increased scrutiny over image manipulation and data integrity, the adoption of more systematic peer review checklists, and ultimately, a broader "reproducibility crisis" conversation that has reshaped expectations for rigor in some fields. The scandal also affected stem cell research funding and public perception, particularly regarding human therapeutic cloning.

Dr. Lewin's criticism, however, proved somewhat prescient regarding ongoing debates about peer review quality at high-impact journals. Concerns about rushed review processes for high-profile papers have continued (though with incremental improvements), and major retractions still occur across all top journals.

## 3. PREDICTIONS

Since this is an opinion commentary rather than a predictive piece, the article doesn't make explicit forward-looking claims. However, the implicit arguments suggest:

- **The "no one comes out of this business looking good" point was prescient**: In 2006-2012, investigations revealed misconduct in papers across *Cell*, *Nature*, and *Science*, validating that research fraud was not unique to one journal.
- **"Every journal that publishes papers worth reading has published papers worth retracting"**: This has remained true, with high-profile retractions continuing across all top-tier outlets.
- **"Rigorous review" debate persists**: The trade-off between speed/publicity and thorough scrutiny continues, though with some improved image-analysis tools and verification standards.

What did evolve: the scientific community developed better tools for detecting image manipulation and has gradually (if slowly) improved reproducibility standards.

## 4. INTEREST

**Rating: 4/10**

While relevant to understanding the 2006 stem cell scandal, the article focuses on journal politics and peer-review finger-pointing rather than substantive biotech developments or their downstream impacts. It offers modest insight into scientific publishing dynamics but is not essential reading for understanding stem cell advances or biotech pipelines.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20060112-plenty-tar-go-around.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_